Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04493424 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT04493424 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 108 participants.
The verdict
NCT04493424, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
This study is open to people with palmoplantar pustulosis who took part in previous clinical studies of a medicine called spesolimab. Participants who benefited from spesolimab treatment in the previous studies can join this study. The purpose of this study is to find out how safe spesolimab is and whether it helps people with palmoplantar pustulosis in the long-term. Participants are in this study for up to 5 years. During this time they visit the study site every month to get spesolimab injections under the skin. At study visits, doctors check the severity of participants' palmoplantar pustulosis and collect information on any health problems of the participants.
Interventions
- DRUG Spesolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2020-09-04 |
| Est. Completion | 2023-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04493424
The ClinicalTrials.gov registry entry for NCT04493424 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Spesolimab is the first listed.
NCT04493424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04493424 about?
NCT04493424 is a clinical study titled "A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab". This study is open to people with palmoplantar pustulosis who took part in previous clinical studies of a medicine called spesolimab. Participants who benefited from spesolimab treatment in the previous studies can join this study. The purpose of this study is to find out how safe spesolimab is and...
What is the current status of trial NCT04493424?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2020-09-04. Estimated completion is 2023-05-15.
What interventions are being tested in trial NCT04493424?
The interventions under investigation include: Spesolimab (DRUG).
Who is sponsoring clinical trial NCT04493424?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.